In the third quarter, Gladstone Institutional Advisory LLC initiated a position in Madrigal Pharmaceuticals by acquiring 1,093 shares at a total cost of approximately $501,000, according to the latest SEC Form 13F filing. This move adds to a wave of activity among major funds: Adage Capital Partners GP L.L.C. boosted its holding by 96.3% to reach 376,163 shares, Norges Bank entered with a new position valued at over $53 million, Invesco Ltd. expanded its stake by more than 50% to 200,356 shares, BNP Paribas Financial Markets lifted its exposure by nearly 19-fold to 69,037 shares, and Artisan Partners Limited Partnership increased its ownership by 46.3% to 201,571 shares. Collectively, hedge funds and institutional investors now control 98.5% of Madrigal’s outstanding shares.

Madrigal Pharmaceuticals reported a debt-to-equity ratio of 0.54 and maintains robust liquidity metrics, including a quick ratio of 3.26 and a current ratio of 3.44, underscoring its ability to fund ongoing clinical development without heavy reliance on external financing. The company’s market capitalization stands at $11.7 billion, reflecting investor confidence in its late-stage pipeline. Despite negative net margins around 39%, Madrigal’s Phase 3 candidate for nonalcoholic steatohepatitis (NASH) remains a potential catalyst for revenue growth and margin improvement upon approval.

Over the past three months, company insiders have sold 77,056 shares valued at more than $41 million, including sales by Carole Huntsman and CFO Mardi Dier, which reduced their combined holdings by over 40%. While insider selling can raise questions about near-term expectations, the broader analyst community remains constructive: one research firm has assigned a strong-buy rating, twelve issue buy recommendations, two maintain holds and one carry a sell rating, resulting in an overall consensus of moderate buy. Recent research notes highlight the upcoming Phase 3 readout as a pivotal event that could drive the stock’s next directional move.